California
Prescription drug spending and prescribing in California, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $27.3B for prescriptions written in California, the 1st most of 52 states and territories, and 3.3% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $27.3B
- Medicaid drugs, 2025: $18.3B
- Opioid share of claims: 3.3%
- Life-science raises, 2 years: $9.8B
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | California | United States | Difference |
|---|---|---|---|
| Opioids | 3.3% | 3.5% | -6% |
| Antibiotics | 4.4% | 4.4% | +0% |
| Antipsychotics | 1.7% | 1.7% | -4% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of California's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Ciclesonide | 6.7× | 130,271 |
| Dabigatran Etexilate Mesylate | 4.7× | 326,030 |
| Insulin Nph Human Isophane | 3.9× | 210,089 |
| Diph,pertuss(Acell),tet Vac/Pf | 3.3× | 78,623 |
| Fluocinonide | 2.6× | 171,251 |
| Syringe-Needle,insulin,0.5 Ml | 2.6× | 106,947 |
| Icosapent Ethyl | 2.6× | 463,278 |
| Terazosin Hcl | 2.5× | 297,735 |
| Benazepril Hcl | 2.5× | 477,524 |
| Finerenone | 2.3× | 83,726 |
Biggest Medicaid Drugs
What California's Medicaid program paid pharmacies, before rebates; see every drugLife-Science Fundraising
476 Form D raises by companies based in California in the last two years; the 10 largest. See all raises- Neuralink Corp.$649M · Biotech · Jun 12, 2025
- Eikon Therapeutics, Inc.$351M · Biotech · Feb 28, 2025
- GRAIL, Inc.$325M · Biotech · Nov 7, 2025
- Olema Pharmaceuticals, Inc.$250M · Pharma · Dec 12, 2024
- MapLight Therapeutics, Inc.$188M · Biotech · Jul 28, 2025
- Epicrispr Biotechnologies, Inc.$177M · Biotech · Aug 26, 2026
- RAPT Therapeutics, Inc.$150M · Biotech · Jan 3, 2025
- Electra Therapeutics, Inc.$134M · Biotech · Oct 30, 2025
- Jasper Therapeutics, Inc.$132M · Biotech · Aug 5, 2026
- NewLimit, Inc.$130M · Biotech · May 15, 2025
State Attorney General Health-Care Cases
Antitrust cases California joined, newest first; see every case- Plaintiff States and FTC v. CVET TOPCO, L.P. et al.2026 · Pending
- People v. Eli Lilly & Co. et al., No. 23STCV00719 (Super. Ct. L.A. Cty. Jan. 12, 2023)2023 · Pending
- FTC et al. v. Vyera Pharmaceuticals, No. 1:20-cv-00706 (S.D.N.Y. Apr. 19, 2020)2020 · Final judgment
- State of California v. Teva Pharmaceutical Industries, Ltd. et al., No. 2:19-cv-03281 (E.D. Pa. 2019)2019 · Settled
- California et al. v. Teikoku Seikayu Co.(Lidoderm), No. 3:18-cv-00675 (N.D. Cal. 01/31/18)2018 · Settled
- State of California ex rel. Becerra v. Watson Laboratories, Inc., No. 17-cv-00562 (N.D. Cal. Feb. 3, 2017)2017 · Settled
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- FTC and California ex rel. Brown v. Watson Pharmaceuticals No. CV-09-00598 (C.D. Cal Feb. 12, 2009)2009 · Dismissed
- Florida et al. v. Abbott Laboratories et al., No. 1:08-cv-00155-SLR (D.Del. 2007)2007 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
Other States
Alabama · Alaska · Arizona · Arkansas · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG